Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma

Haematologica

Volumn 97, Issue 10, 2012, Pages 1614-1616

  Schmelz, Monika ^a   Montes Moreno, Santiago ^b   Piris, Miguel ^b   Wilkinson, Sarah T ^c   Rimsza, Lisa M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD20 ANTIGEN; CD38 ANTIGEN; CELL MEMBRANE PROTEIN; HLA DR ANTIGEN; INTERFERON REGULATORY FACTOR 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5; X BOX BINDING PROTEIN 1;

CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL MEMBRANE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LETTER; OUTCOME ASSESSMENT; PHENOTYPE; PLASMABLASTIC LYMPHOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTIGENS, CD8; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL;

EID: 84867260540     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.060186     Document Type: Letter

References (8)

1. Stein H, Harris NL, Campo E. Plasmablastic lymphoma. (WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. Lyon: IARC Press, 2008;256-7.
2. Campo E, Chott A, Kinney MC, Leoncini L, Meijer CJ, Papadimitriou CS, et al. Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology. 2006;48(5):481-504.
3. Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, et al. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia. 2004;18(1):146-55.
4. Montes-Moreno S, Gonzales-Medina A-R, Rodriguez-Pinilla SM, Maestre L, Sanchez-Verde L, Roncador G, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: Immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010;95(8):1342-9.
5. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, et al. Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival irrespective of other prognostic factors: A follow-up study to the NIH Director's Challenge Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103(11):4251-8.
6. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.
7. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, et al. Loss of major histocompatibility class II expression in nonimmune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 2006;107(3): 1101-7.
8. Wilkinson ST, Vanpatten KA, Fernandez DR, Brunhoeber P, Garsha KE, Glinsmann-Gibson BJ, et al. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood. 2012;119 (6):1459-67.